Tracer library / [225Ac]Ac-DOTA-TOC

Structure of DOTA-TOC (unlabelled parent compound, from PubChem) — Unlabelled parent compoundPubChem CID 158782

[225Ac]Ac-DOTA-TOC

Also written as DOTATOC; DOTA-TOC

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Neuroendocrine neoplasms Peptide receptor radionuclide therapy

What it is

Compound class: Radiolabeled somatostatin analogue (DOTA-conjugated peptide, DOTATOC)
Target / mechanism: Somatostatin receptor (SSTR) PMID 24516620
Clinical application: Neuroendocrine tumors, including somatostatin receptor-expressing metastatic pancreatic NET liver metastases PMID 18519789
Theranostic pair: [68Ga]Ga-DOTA-TOC

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy.
2020 · Clin Nucl Med · Clinical study

Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-TOC, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 5 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68. Stage set/updated at stage 39 from PMID 31977472: 'We present here a case with β-radiation-refractory metastatic neuroendocrine tumors, who demonstrated an excellent therapy response after 1 cycle of Ac-DOTATOC'.